Paul Watkins, M.D.

Director, Institute for Drug Safety Sciences Howard Q. Ferguson Distinguished Professor Professor of Medicine Professor of Environmental Sciences and Engineering

Paul Watkins, M.D., is director of the Institute for Drug Safety Sciences at the UNC Eshelman School of Pharmacy and the Howard Q. Ferguson Distinguished Professor in the Division of Pharmacotherapy and Experimental Therapeutics.

Watkins is interested in mechanisms that underlie serious liver injury due to drugs. His research spans preclinical models to patients in clinical trials and utilizes current genomics technologies, including genetics, transcriptomics and metabolomics.

Read More
More

 

Positions Held

University of North Carolina

  • Howard Q. Ferguson Distinguished Professor of Pharmacy 7/1/2016 – present
  • Director, UNC School of Pharmacy Institute for Drug Safety Sciences 9/1/08 – present
  • Professor of Experimental Therapeutics (School of Pharmacy) – 8/1/99 – present
  • Verne S. Caviness Distinguished Professor of Medicine – 8/1/99 – 7/1/11
  • Professor of Medicine (School of Medicine) – 8/1/99 – present
  • Professor of Toxicology (School of Public Health) – 5/1/07 – present
  • Director, General Clinical Research Center – 8/1/99 – 5/19/08
  • Director, Translational and Clinical Sciences Institute – 1/15/07 – 9/1/08

University of Michigan

  • Professor of Pharmacology – 9/1/98 – 7/31/99
  • Professor of Medicine – 9/1/97 – 7/31/99
  • Director, General Clinical Research Center – 6/1/91 – 7/31/99
  • Associate Professor of Medicine – 6/91 – 7/31/99
  • Associate Director, Clinical Research Center – 3/1/91 – 6/1/91
  • Assistant Professor of Medicine – 8/86 – 6/91

Medical College of Virginia

  • Assistant Professor of Medicine – 7/85 – 7/86
  • Instructor – Department of Medicine – 7/84 – 7/86

Honors and Awards

  • 2016 Society of Toxicology Best Toxicology Manuscript: “A Systems Biology Approach Utilizing a Mouse Diversity Panel Identifies Genetic Differences Influencing Isoniazid-Induced Microvesicular Steatosis”
  • 2015 recipient of the Rawls-Palmer Progress in Medicine Award from the American Society of Clinical Pharmacology and Therapeutics
  • “Highly Cited Researcher” – Among most cited authors in pharmacology worldwide 1983-2014 (ISIHighlyCited.com)
  • Society of Toxicology Best Manuscript of 2015
  • Agilent Thought Leader Award # 2636 – 2013, 2014.
  • Society of Toxicology Biological Modeling Specialty Section – 2014 Best Biological Modeling Paper: “MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics”
  • State-of-the-Art-Lecture at Digestive Disease Week, the annual meeting of the American Gastroenterology Association, Chicago, 2011
  • Fellow, American Gastroenterology Association 2009
  • Sterling Lecture: Tufts University Medical School 2009
  • O’Doul Visiting Professorship – University of Kansas 2009
  • Outstanding Published Paper “Advancing the Sciences of Risk Assessment” – Society of Toxicology, 2009
  • Goldberg Lecture: University of Chicago, 2008
  • NIH, MERIT Award, 1998-2008
  • Association of American Physicians, 2006
  • Annual National Clinical Research Meetings
  • Presented “State of the Art” Plenary Lecture, 4/28/05
  • The Burton Shatz Visiting Professor, Washington University, St Louis 6/30/04
  • Honorary Membership – Society of Toxicologic Pathology – Presented after Key Note Lecture at 2004 Annual Meeting in Salt Lake City
  • The Hyman Zimmerman State-of-the-Art Lecture, Annual meeting of the American Association for the Study of Liver Diseases, 11/1/04
  • Graduate Student Research Prize (1st place, Shefali Malhotra), ISSX meeting in Munich, Germany – 2001
  • Food and Drug Administration Visiting Professor – 2000
  • Therapeutic Frontiers Lecture Award, American College of Clinical Pharmacy, 1998
  • Pfizer Visiting Professor in Clinical Pharmacology to Tufts/New England Medical Center, 1996
  • 1995 Best Manuscript Award – Drug Metabolism and Disposition
  • Dean’s Award to “Highly Meritorious Faculty,” 1994
  • Fellow, American College of Physicians, 1994
  • American Society for Clinical Investigation, 1993
  • Veterans Administration Career Development Awards
  • Associate Investigator, 7/84-7/86
  • Research Associate, 1/87-1/91

Current Grant Support

NIH-UO1 DK065201

Title: “Drug Induced Liver Injury Network”

PI: Paul B. Watkins

Project period: 9/1/13 – 8/31/2018

Total direct cost: $1,250,000

Effort: 20 percent

 

NIH/National Center for Advancing Translational Sciences:1UL1TR001111-01

Title: “North Carolina Translational & Clinical Sciences Institute (NC TraCS)”

PI: Marschall S. Runge

“Drugs, Devices and Diagnostics Development (4D) Strategic Initiative”

Co-Director: Paul B. Watkins

Project period: 9/26/13 – 4/30/2018

Effort: 5 percent

 

“Organ Toxicity Biomarker Core,” subcontract with UNC CTSA grant (above)

Sub-award to Hamner Institutes

Funding provided by NC TraCS pilot grant program

PI: Paul B Watkins

Project period: 9/26/13 – 4/30/2014

Effort: 5 percent

 

NIH/NIGMS, 1T32GM086330-01

Title: “UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program”

PI: Benjamin, Brouwer and Watkins (Multiple PIs)

Project Period: 7/1/11 – 7/31/16

 


INSTITUTION AND LOCATION DEGREE Completion Date FIELD OF STUDY
Cornell University B.A. Chemistry
Cornell University M.D.
N.Y. Presbyterian Hospital – Weill Cornell Medical Center Internship/Residency

Paul Watkins News